Nuclear medicine applications in prostate cancer
Loading...
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Leslie, S.
Leslie, S.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2023-05-30
Supervisors
Type
Journal Article
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cancer patients
prostate cancer
theranostics
radionuclide therapy
prostate cancer
theranostics
radionuclide therapy
ANZSRC Field of Research Code (2020)
Citation
Vyas, M. & Leslie, S. (2023). Nuclear medicine applications in prostate cancer. StatPearls, 2023 January [Article] PMID: 37276321. https://pubmed.ncbi.nlm.nih.gov/37276321/
Abstract
In recent years, the incidence of prostate cancer has been the highest ever recorded due to earlier and more accurate detection and an increase in the average lifetime. Prostate cancer is now the second most common malignancy amongst all cancers in men and the fourth most common overall.
The American Cancer Society has identified prostate cancer as the second leading cause of mortality from oncological causes in the United States, accounting for an estimated 268,490 newly diagnosed cases and 34,500 deaths in 2022. The National Cancer Institute predicts that the average American man has an 11% risk of being diagnosed with prostate cancer at some point in life and a 2.5% overall risk of dying from the disease.
Globally, there were more than 1.4 million new cases of prostate cancer diagnosed worldwide in 2020, accounting for 375,304 deaths.[1][2][3] Prostate cancer has been identified as the most commonly diagnosed malignancy in 112 countries worldwide and the leading cause of cancer mortality in 48.[2][4]
Timely diagnosis leading to earlier and more effective treatment is required to reduce the significant morbidity and mortality rates. Nuclear medicine has several new and revolutionary prostate cancer detection, localization, staging, and treatment tools utilizing targeted therapy.[5][6] The expanding role nuclear medicine plays in managing prostate cancer will be discussed in detail in the following review.
[...]
Radiopharmaceuticals for Bone Scan Imaging
Tc-99m Diphosphonates (99mTc-MDP) Bone Scan
[F-18] F-18-Sodium Fluoride Bone Scan
Radiopharmaceuticals for Prostate Cancer Imaging
[F-18] F-Fluciclovine (FACBC) PET Scan
PSMA-Binding Radionuclide Imaging
[Ga-68] Ga-68-PSMA-11
[F-18] F-18-PSMA piflufolastat (DCFPyL)
Tc-99m-PSMA Radioligands
Indium-111 Capromab Pendetide Imaging
Tips for PSMA-PET Interpretation
Challenges to PSMA-PET Interpretation
Summary: PET-Based Radionuclide Imaging in Prostate Cancer
Targeted Radiopharmaceutical Therapy for Prostate Cancer (Theranostics)
Lutetium-177 Radioligand Therapy
Patient Selection for Lu-177-PSMA Treatment
Treatment Protocols for Lu-177-PSMA Therapy
Other PSMA Ligand Therapies
Other Nuclear Medicine Therapies in Prostate Cancer
Summary of Principal Therapeutic Targeted Radiopharmaceuticals
Publisher
StatPearls
Permanent link
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved